title: Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.
abstract: Canagliflozin (CFZ) is a member of new class of glucose lowering agents, sodium-glucose co-transporter (SGLT) inhibitors, which got approval by food and drug administration. It has insulin independent action by blocking the transporter protein SGLT2 in the kidneys, resulting in urinary glucose excretion and reduction in blood glucose levels. In clinical trials, CFZ significantly decreased HbA1c level when administered either as monotherapy or as combined therapy with other anti-diabetic drugs. Intriguingly, it showed additional benefits like weight reduction and lowering of blood pressure. The commonly observed side effects were urinary and genital infections. It has exhibited favorable pharmacokinetic and pharmacodynamic profiles even in patients with renal and hepatic damage. Hence, this review purports to outline CFZ as a newer beneficial drug for type 2 diabetes mellitus.
authors.affiliation: Jagriti Bhatia, Nanda Gamad, Saurabh Bharti, Dharamvir Singh Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110029, India.
authors.forename: Jagriti
authors.initials: J
authors.lastname: Bhatia
authors.affiliation: Jagriti Bhatia, Nanda Gamad, Saurabh Bharti, Dharamvir Singh Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110029, India.
authors.forename: Nanda
authors.initials: N
authors.lastname: Gamad
authors.affiliation: Jagriti Bhatia, Nanda Gamad, Saurabh Bharti, Dharamvir Singh Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110029, India.
authors.forename: Saurabh
authors.initials: S
authors.lastname: Bharti
authors.affiliation: Jagriti Bhatia, Nanda Gamad, Saurabh Bharti, Dharamvir Singh Arya, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110029, India.
authors.forename: Dharamvir Singh
authors.initials: DS
authors.lastname: Arya
keywords: Canagliflozin; Clinical trial; Safety profile; Sodium-glucose co-transporter 2; Type 2 diabetes mellitus